Consolidated financial results and position
|Ratio of operating income
|Ratio of ordinary profits
|Profit attributable to owners of parent(¥million)||1,753||1,174||(542)||878||1,550|
|Ratio of Shareholders'
Operating income and ratio of operating income
Ordinary profits and ratio of ordinary profits
Profit attributable to owners of parent
Shareholders equity and ratio of shareholders equity
About the pharmaceutical industry
In the pharmaceutical industry, while creation of innovative drugs is anticipated through technological innovation and industry-government-academia collaboration towards providing personalized medicine or “precision medicine”, introduction of cost-effective assessments on the drug pricing system is considered due to impact on the health insurance budget. Further improvement of productivity and efficiency is expected for the pharmaceutical industry. In revising the "Comprehensive Strategy to Strengthen the Pharmaceutical Industry" developed by MHLW, the following six focus items were set out aiming at becoming a “drug discovery powerhouse” in the global market: 1) Improvement of R&D environment, 2) Cost reduction and efficiency improvement through regulatory reform, 3) Improvement of productivity and manufacturing infrastructure building for medicinal products,4) Environment and infrastructure improvement for appropriate evaluation, 5) International expansion of Japan-origin pharmaceuticals, 6) Creation of players who can merge medical care and services/Enhancing the creation of global venture companies to promote renewal of the drug discovery industry. Pharmaceutical industry is expected to be forward-looking and convert to the industrial structure that is internationally competitive. Companies will likely accelerate efforts to bolster new drug development capacity towards promotion of innovation and discovery of innovative drugs that can contribute to improve the quality of medical care. This will lead to continued increases in outsourcing with the aim of further improving productivity and efficiency.
Under such circumstances, we are working to further enhance the foundations and individual services of each of the group’s businesses, provide PVC (Pharmaceutical Value Creator) model that combines value chains, and IPM (Innovative Pharma Model) model or new business solutions to pharmaceutical companies with marketing authorization licenses possessed by our group. CMIC group will meet the changing needs of medical and pharmaceutical industry in a timely manner. For the next fiscal term we forecast both sales and operating income to increase compared with this consolidated fiscal year, and operating income is expected to be the highest-ever profit.
|Profit attributable to owners of parent||1,550||1,700||9.6%|
Operating income and ratio of operating income
Forecast for FY ending Sept. 2018 (by segment)
Our core business, CRO business, will continue to support foreign companies and companies from other industries entering the Japanese market as a leading domestic company, enhance our business activities in the United States and Asia, and meet the increasingly sophisticated development needs including regenerative medicine and oncology.
Sales and profit growth is expected for CRO business due to strong order intake continuing for clinical operations and other areas.
CDMO business is moving forward with establishing a structure for total service provision for drug manufacturing that includes formulation design, investigational new drug manufacturing, and commercial production. We will continue to improve technical capabilities, further promote low-cost production, and strengthen competitiveness through strategic capital investments.
Though revenue increase is expected for CDMO business due to production increase of both new and existing projects, because of start-up cost for the new injection building at Ashikaga Plant that is scheduled to start operating in October 2018, operating income is expected to be the same level as that of this fiscal year.
For CSO business, amid the qualitative change of MR activities by pharmaceutical companies, we will aim to expand the market share by increasing the order intake of MR dispatching business and promoting new service models.
Sales and profit growth is expected for CSO business thanks to the steady expansion of commercial activities.
Healthcare business will focus on order intake while maintaining our focus on quality and compliance for SMO operations.
Sales and profit growth is expected for SMO business due to strong new order intake continuing for SMO business.
Innovative Pharma Model business
While revenue growth is expected for IPM business following the sales increase of the orphan drug business, because of R&D cost for orphan drugs and diagnostics, operating loss is expected. We will aim to expand sales and provide new solutions towards profitability.
Year end dividend(yen)
※The year end dividend for FY2017 : Ordinary dividend \20.0, Commemorative dividend \2.5(25th anniversary).
See “Dividends” in the Stock Information for details of past.